Key information

🔎 Fund Overview

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases, such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy, and other conditions. The Company’s lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barriers to the S2R complex, and through its modulation, S2R restores the normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling lipid membrane-bound protein trafficking, and others.